Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Molecular Partners logo — Pioneering DARPin Therapeutics for Patients

Molecular Partners

Pioneering DARPin Therapeutics for Patients

Founded 2004 Switzerland Switzerland 174 employees Post-IPO Equity Total: $179.96M Biotechnology, Pharmaceutical

General Information

Company Name Molecular Partners
Founded Year 2004
Location Switzerland Switzerland
Founders / Decision Makers
Team member Team member
Employees 174
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Molecular Partners. To contact Molecular Partners, visit molecularpartners.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Molecular Partners compare?

A PDF of Molecular Partners and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Molecular Partners soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Molecular Partners

Molecular Partners is a clinical-stage biotech company founded in 2004 and headquartered in Switzerland. The company specializes in pioneering DARPin therapeutics, which represent a new class of custom-built drugs aimed at addressing medical challenges that are difficult for other modalities to tackle. With a primary focus on oncology, Molecular Partners has several programs in various stages of pre-clinical and clinical development. The company leverages the advantages of DARPins to offer unique solutions to patients through its proprietary programs and partnerships with leading pharmaceutical companies. Notably, Molecular Partners received a Fr.40.00M Post-IPO Equity investment on 28 October 2020, with the investment coming from Novartis. This demonstrates confidence from a major player in the pharmaceutical industry and highlights the potential of Molecular Partners as a significant player in the biotech and pharmaceutical industries.

Business keywords: biotech, DARPin therapeutics, clinical-stage, oncology, virology, pharmaceutical research, biopharmaceutical, small protein therapies, intellectual property, immunology, ophthalmology, collaborations, serious diseases, top biotech investors

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Fr.40.00M 1
Novartis
Novartis
28 Oct 2020
Post IPO Equity Fr.80.20M 4
Suvretta Capital Management Camber Capital Corp
Suvretta Capital Management, Camber Capital Corp +2
06 Jul 2020
Series B $44.20M 5
Index Ventures BB Biotech Ventures Endeavour Vision
Index Ventures, BB Biotech Ventures +3
16 Dec 2009
Series A $15.56M -
14 Aug 2007

Molecular Partners Alternatives & Competitors

View All Alternatives
Molecular Partners vs
Antengene
Antengene China

Treating Patients Beyond Borders.

Series C
69 employees
Biopharma, Biotechnology
Compare Molecular Partners vs Antengene
Molecular Partners vs
Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. United States

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness
Compare Molecular Partners vs Lisata Therapeutics, Inc.
Molecular Partners vs
AVEO Oncology
AVEO Oncology United States

Committed to delivering medicines that provide a better life for patients with cancer.

Post-IPO Equity
197 employees
Biotechnology, Health Care
View all alternatives

FAQ About Molecular Partners

Pioneering DARPin Therapeutics for Patients
Molecular Partners was founded in 2004.
Molecular Partners is headquartered in Switzerland.
Molecular Partners operates in Biotechnology and Pharmaceutical. Its work centres on biotech, DARPin therapeutics, clinical-stage and oncology.
Molecular Partners has approximately 174 employees.
Molecular Partners has completed 4 funding rounds, raising a total of $179.96M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Molecular Partners include Antengene, Lisata Therapeutics, Inc., AVEO Oncology, Silver Creek Pharmaceuticals, Olema Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Molecular Partners and Antengene are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Molecular Partners, https://bouncewatch.com/company/molecular-partners, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout